This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk
Blood Cancer Talks
Claim This Podcastby Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
4.8(86 reviews)
72 episodes
Updated Bi-weekly
Accepts GuestsHas SponsorsLocation 🇺🇸
37
Podcast Authority
BetaPoorBased on show quality, social media presence, reviews, charts, and more
Quality9
Social0
YouTube76
Engagement85
Podcast Overview
This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk
Language
🇺🇲
Publishing Since
7/8/2022
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
37
Podcast Authority
BetaPoorBased on show quality, social media presence, reviews, charts, and more
Quality9
Social0
YouTube76
Engagement85
5
Excellent Areas
2
Good Performance
12
Growth Opportunities
excellent
Episode Length
46 minutes
Performing excellently!
good
Show Notes Quality
3.0/5
Recommendations available
Unlock the full report to see detailed tips
needs improvement
Publishing Consistency
Every 18 days
Recommendations available
Unlock the full report to see detailed tips
+16 More Metrics
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
What's Included in Your Full Report
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
Get your free podcast insights report
See how your show performs across every key metric
Instant delivery
No spam
Attract Better Guests
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Secure Sponsorships
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Grow Your Audience
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
1 verified contact email on file for Blood Cancer Talks
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
May 19, 2026
Episode 71. Management of Newly Diagnosed Multiple Myeloma with Dr. Vincent Rajkumar
Host Ashwin Raj and Eddie interview Dr. Vincent Rajkumar, Mayo Clinic Professor, discussing newly diagnosed multiple myeloma management, from workup to maintenance strategies.
February 27, 2026
Episode 70. ASH 2025 Myeloid Neoplasm Roundup with Dr. Curtis Lachowiez
<p><br>In this episode, we dive deep into ASH 2025 updates on myeloid malignancies with Dr. Curtis Lachowiez. From the plenary halls of ASH 2025 to long-term follow-up of Aza/Ven/Gilteritinib, we unpack what the latest evidence means for the future of AML management.<br><strong><br>1. PARADIGM Trial (Plenary Session, Abstract 6)</strong></p><p>Fathi A, Perl A, Fell G, et al. Results from PARADIGM – a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. Blood 2025;146(Suppl 1):6.</p><p><a href="https://doi.org/10.1182/blood-2025-6">https://doi.org/10.1182/blood-2025-6</a></p><p>ClinicalTrials.gov: <a href="https://clinicaltrials.gov/ct2/show/NCT04801797">NCT04801797</a></p><p><strong><br>2. VICEROY Study – Aza/Ven/Gilteritinib Triplet (Abstract 654)</strong></p><p>Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed FLT3mut+ AML ineligible for intensive induction chemotherapy: Interim results from the phase 1/2 VICEROY study. Blood 2025;146(Suppl 1):654.</p><p>ClinicalTrials.gov: <a href="https://clinicaltrials.gov/ct2/show/NCT05520567">NCT05520567</a></p><p><strong><br>3. Long-Term Follow-Up of Aza/Ven/Gilteritinib in FLT3-Mutated AML (Abstract 45)</strong></p><p>Azevedo RS, et al. Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated acute myeloid leukemia. Blood 2025;146(Suppl 1):45.</p><p>Original publication: Short NJ, Daver N, DiNardo CD, et al. J Clin Oncol 2024;42:1499–1508. <a href="https://doi.org/10.1200/JCO.23.01911">https://doi.org/10.1200/JCO.23.01911</a></p><p>ClinicalTrials.gov: <a href="https://clinicaltrials.gov/ct2/show/NCT04140487">NCT04140487</a></p><p><strong><br>4. PRISM-AML Score (Abstract 453)</strong></p><p>Lachowiez CA, et al. Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: A multinational retrospective cohort study. Blood 2025;146(Suppl 1):453.</p><p>Interactive Calculator: <a href="https://prism-aml.com">https://prism-aml.com</a></p><p><strong><br>5. Additional Studies Referenced in Discussion</strong></p><p>• <strong>VIALE-A Trial: </strong>DiNardo CD, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020;383:617–629. (NCT02993523)</p><p>• <strong>VERONA Trial: </strong>Randomized study of Aza-Ven vs. Aza vs. placebo in MDS (discussed as a negative study)</p><p>• <strong>4-Gene Classifier (mPRS): </strong>Bataller A, et al. Prognostic risk signature in patients with AML treated with HMA and venetoclax. Blood Adv 2024;8(4):927–935. <a href="https://doi.org/10.1182/bloodadvances.2023011757">https://doi.org/10.1182/bloodadvances.2023011757</a></p><p>• <strong>LACEWING Trial: </strong>Azacitidine plus gilteritinib vs. azacitidine plus placebo in FLT3-mutated AML (discussed as a negative study)</p><p> </p>
January 22, 2026
Episode 69. ASH 2025 Lymphoma Roundup with Dr. Carla Casulo
<p>BloodCancerTalks: ASH 2025 Lymphoma Roundup</p><p>Guest: Dr. Carla Casulo, Associate Professor, Wilmot Cancer Centre, University of Rochester</p><p><strong>Abstracts Discussed</strong></p><p><strong>Follicular Lymphoma</strong></p><p>EPCORE-FL1 (Falchi) - Epcoritamab plus lenalidomide-rituximab (R2) in relapsed/refractory FL</p><p>Theme: Bispecific antibody combinations in R/R FL; comparing to other approaches</p><p> </p><p><strong>Diffuse Large B-Cell Lymphoma (DLBCL) - Elderly/Unfit Patients</strong></p><p>MorningSun (Sharman) - Mosunetuzumab monotherapy in patients ≥80 years or chemo-ineligible</p><p>EPCOR-DLBCL-3 (Vitolo) - Epcoritamab monotherapy in elderly patients</p><p>R-Pola-Glo - Rituximab-polatuzumab-glofitamab combination in older/frail patients</p><p>Theme: Single-agent and combination bispecific strategies for elderly and frail DLBCL patients</p><p> </p><p><strong>DLBCL - First-Line Treatment</strong></p><p>SMART STOP (Westin) - Chemotherapy-free approach using lenalidomide, tafasitamab, rituximab, acalabrutinib (ULTRA regimen)</p><p>FrontMIND - Tafasitamab-lenalidomide added to R-CHOP</p><p>Theme: Chemotherapy-sparing and chemo-intensification strategies in newly diagnosed DLBCL</p><p> </p><p><strong>DLBCL - Relapsed/Refractory</strong></p><p>DALY 2-EU (Borchmann) - Dual CD19/CD20 CAR-T (zamto-cel) versus R-GemOx in transplant-ineligible patients</p><p>Theme: Expanding CAR-T eligibility; treatment selection in transplant-ineligible R/R DLBCL</p><p> </p><p><strong>Hodgkin Lymphoma</strong></p><p>SWOG 1826 - 3-year update: Nivolumab-AVD versus brentuximab-AVD</p><p>HD21 - 5-year update: PET-adapted BrECADD versus BEACOPP</p><p>Theme: Long-term outcomes and treatment selection in newly diagnosed Hodgkin lymphoma</p><p><strong> </strong></p><p><strong>Burkitt Lymphoma</strong></p><p>ZUMA-25 (Van Dorp) - Brexucabtagene autoleucel (Brexu-cel) in relapsed/refractory Burkitt</p><p>Theme: CAR-T therapy for the challenging population of R/R Burkitt lymphoma</p><p> </p><p><strong>Mantle Cell Lymphoma - First-Line</strong></p><p> </p><p>TrAVeRse - Acalabrutinib, venetoclax, rituximab</p><p>GLOVe - Glofitamab, lenalidomide, venetoclax (high-risk MCL)</p><p>BOVen - Zanubrutinib, obinutuzumab, venetoclax (older patients)</p><p>MAVO - Acalabrutinib, venetoclax, obinutuzumab</p><p>Window-3 - Acalabrutinib-rituximab followed by brexu-cel (high-risk MCL)</p><p>Theme: Chemotherapy-free combinations in newly diagnosed mantle cell lymphoma</p>
72 total episodes available with 1 transcripts
Similar Podcasts
Discover related shows you might enjoy
WolverHeme Happy Hour
Bernard Marini, Anthony Perissinotti, et al.
Two Onc Docs
Sam and Karine
Blood Podcast
American Society of Hematology
Hematologic Oncology Update
Dr. Neil Love
VJHemOnc Podcast
VJHemOnc
The Hematologist
The Hematologist
Plenary Session
Vinay Prasad, MD MPH
ASTCT Talks
ASTCT
HemeTalks: Conversations in Hematology Education
American Society of Hematology
EHA Unplugged
European Hematology Association
Oncology Brothers
Oncology Brothers
Harrison's PodClass: Internal Medicine Cases and Board Prep
AccessMedicine
The Curbsiders Internal Medicine Podcast
The Curbsiders Internal Medicine Podcast
Core IM | Internal Medicine Podcast
Core IM Team
The Oncology Nursing Podcast
Oncology Nursing Society
Deep-dive analytics for Blood Cancer Talks
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Blood Cancer Talks?
- How often does this podcast release new episodes?
This podcast updates bi-weekly.
- Where can I listen to this podcast?
This podcast is available on 10 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
No, this podcast does not typically feature guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.